News | April 26, 2024
Divi's Laboratories to expand capacity at an outlay of approx. Rs. 700 Cr
The proposed facility is expected to be operational around January, 2027
The proposed facility is expected to be operational around January, 2027
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Open a printable version of this pageEmail the URL of this page to a friend
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Subscribe To Our Newsletter & Stay Updated
